Project Cure CRC ignites innovation in 2025 with $10.5 million in research, K-SPY debut & renewed RFP

The initiative by the Colorectal Cancer Alliance continues to break boundaries in care

2025-02-13

(Press-News.org) The leading nonprofit Colorectal Cancer Alliance (Alliance) is making bold strides in its mission to put an end to the disease. Its Project Cure CRC research initiative awarded new grants, convened top scientists to spark breakthrough advancements at its Cure CRC Summit, and unveiled K-SPY, a groundbreaking multi-center platform trial for high-risk colorectal cancer cases. Since its launch, Project Cure CRC has received 275 proposals, of which 22 have been approved totaling $10.5 million in awards. The latest awards reflect $2.8 million of the overall funding for urgently needed innovations. With significantly more funds available, the Alliance issues a renewed Project Cure CRC Request for Proposals from researchers with cutting-edge colorectal cancer studies.

“Colorectal cancer is the second deadliest cancer in the nation, yet it is grossly underfunded, causing a tremendous gap in the development of new treatments and therapies,” said Michael Sapienza, CEO of the Colorectal Cancer Alliance. “Project Cure CRC is committed to filling that gap and improving outcomes for the millions of people affected by this disease.”

New Research Grants from Project Cure CRC

Recipients of the most recent Project Cure CRC grants include investigators from across the nation focusing on various topics in colorectal cancer:

Angelique Whitehurst, Ph.D., The University of Texas Southwestern - TSSK6 is a Precision Target in CRC ($200,000)

Melissa Fishel, Ph.D., Indiana University - Ref-1 Redox Signaling as a Target in CRC ($200,000)

Wenhan Zhu, Ph.D., Vanderbilt University Medical Center - Carcinogenic Microbe Rewires Colonocyte Metabolism to Drive CRC Development ($200,000)

Hyunyoung Jeong, Pharm.D., Ph.D., Purdue University - Tryptophanase in Fusobacterium Nucleatum-Mediated CRC Progression and Therapy Resistance ($200,000)

Boyi Gan, Ph.D., The University of Texas MD Anderson Cancer Center - Targeting Ferroptosis as a Vulnerability in BRCA1-deficient CRC ($1.1 million)

Binfeng Lu, Ph.D., Hackensack Meridian Health Center for Discovery and Innovation - Define the Tumor Microenvironment in mCRC with Peritoneal Metastasis and Evaluating Innovative Immunotherapy Strategies for its Treatment ($200,000)

Nilofer Azad, M.D., Sidney Kimmel Comprehensive Cancer Center at John Hopkins - KRAS-vaccination with Next-Gen Immune Checkpoint Inhibition in First -line Maintenance, MSS mCRC ($290,000)

Christopher Lengner, Ph.D., University of Pennsylvania - Targeting Tumor Stroma in CRC to Overcome Resistance to Immunotherapy ($210,000)

Khosrow Rezvani, Ph.D., University of South Dakota, Nanoparticle-Based Targeted Delivery and Release of Veratridine: A Novel Strategy for Suppressing mTORC2 Signaling Pathway and Mitochondrial Metabolism in CRC ($200,000)

Alliance Debuts K-SPY at Cure CRC Summit

Last December, the Alliance brought together 150 leading experts in colorectal cancer research at its second annual international Cure CRC Summit. The meeting sparked innovation, promoted collaboration, and introduced cutting-edge strategies to advance research and enhance patient care. During the summit, the Alliance and CRC leaders strategized and planned the launch of K-SPY, an adaptive clinical trial platform aimed at transforming colorectal cancer care through personalized treatments, faster access to therapies, and improved outcomes. K-SPY tests multiple therapies simultaneously, using real time data and a statistical approach to refine treatments dynamically. The platform aims to increase the five-year survival rate of metastatic colorectal cancer (mCRC) from 13% to 35%, a primary goal of the Alliance.

Renewed Request for Proposals:

Based on input from the Cure CRC Summit, the Alliance renewed the Project Cure CRC Request for Proposals. Researchers are encouraged to submit novel innovative ideas for CRC research with curative intent and special attention given to immunotherapy-based studies and research focused on BRCA1, BRAF, TP53, TME, and associated pathway genes.

The Alliance, the largest nonprofit organization dedicated to ending colorectal cancer, invites the public, corporations, foundations, and philanthropic individuals to join our mission by contributing to Project Cure CRC. For more information on Project Cure CRC, to donate, or to submit a research proposal, please visit colorectalcancer.org/research.

About the Colorectal Cancer Alliance

The Colorectal Cancer Alliance empowers a nation of passionate and determined allies to prevent, treat, and overcome colorectal cancer in their lives and communities. Founded in 1999 and headquartered in Washington, D.C., the Alliance advocates for prevention through initiatives like LEAD FROM BEHIND, magnifies support through BlueHQ, and accelerates research through Project Cure CRC. We are the largest national nonprofit dedicated to colorectal cancer, and we exist to end this disease in our lifetime. For more information, visit colorectalcancer.org.

END

[Attachments] See images for this press release:

ELSE PRESS RELEASES FROM THIS DATE:

Damon Runyon Cancer Research Foundation and St. Jude Children’s Research Hospital invest $1.8 million in childhood cancer research

2025-02-13

New York, New York, and Memphis, Tennessee, February 13, 2025 The Damon Runyon Cancer Research Foundation and St. Jude Children’s Research Hospital have announced their newest class of pediatric cancer research fellows, each of whom will receive funding for four years ($300,000 total) to support an innovative research project with the potential to significantly impact the diagnosis or treatment of one or more pediatric cancers. Launched in 2024, the Damon Runyon-St. Jude Pediatric Cancer Research Fellowship aims to address a funding gap that drives top talent to seek more prevalent opportunities in adult cancer research or the pharmaceutical sector. Fellows are selected by a distinguished ...

New ACS study finds menthol flavored cigarette smoking increases mortality risk vs. non-menthol cigarettes

2025-02-13

In a large, nationwide study led by the American Cancer Society (ACS), researchers found mortality risks for smoking menthol cigarettes were higher than non-menthol cigarettes for death from any cause and cardiovascular diseases, especially heart diseases. Higher risks were evident in individuals who had quit smoking and at high smoking intensities. Black participants currently smoking menthol brands had high increases for some heart diseases with an 88% elevated mortality risk compared to non-menthol cigarettes. ...

Discussing barriers, concerns key for getting older adults vaccinated

2025-02-13

A clear endorsement from their healthcare provider and being supplied information about recommended vaccines before their clinic visit spurred more older Americans to get vaccinated, a new University of Virginia School of Medicine study found. Because immune systems age like the rest of the body, older adults are at higher risk for poor outcomes from infections. But only 15% of Americans ages 50 and older and 25% of Americans ages 65 and older are up to date on all recommended vaccines, including flu, RSV, tetanus and pneumococcal disease. In the study, six primary care clinics across America piloted a new approach to boosting vaccination rates. This included ...

Regular access to therapy dogs boosts first-year students’ mental health

2025-02-13

PULLMAN, Wash. — College students who spent a little bit of free time each week interacting with therapy dogs on campus during their first semester experienced fewer signs of stress and depression than those who did not. That’s according to the PAWs4US study, a new paper published in Pets that examined how regular, long-term access to an animal-assisted drop-in program at Washington State University influenced first-year students’ mental health. The study found that students who engaged with therapy dogs in repeated, unstructured sessions over several months not only ...

The complicated question of how we determine who has an accent

2025-02-13

COLUMBUS, Ohio – How do you tell if someone has a particular accent? It might seem obvious: You hear someone pronounce words in a way that is different from “normal” and connect it to other people from a specific place. But a new study suggests that might not be the case. “People probably don’t learn who has an accent from hearing someone talk and thinking, ‘huh, they sound funny’ – even though sometimes it feels like that’s how we do it,” said Kathryn Campbell-Kibler, author of the study and associate professor of linguistics at The Ohio State University. Accents may be ...

NITech researchers shed light on the mechanisms of bacterial flagellar motors

2025-02-13

When speaking of motors, most people think of those powering vehicles and human machinery. However, biological motors have existed for millions of years in microorganisms. Among these, many bacterial species have tail-like structures—called flagella—that spin around to propel themselves in fluids. These movements employ protein complexes known as the “flagellar motor.” This flagellar motor consists of two main components: the rotor and the stators. The rotor is a large rotating structure, anchored to the cell membrane, that turns the flagellum. On the other hand, the stators are smaller ...

Study maps new brain regions behind intended speech

2025-02-13

Broca’s aphasia is caused by damage to the frontal lobe, leaves patients unable to say what they intend to say First study to identify regions outside the frontal lobe that encode the intent to speak Critical for technology to avoid decoding a patient’s thoughts that are not intended to be spoken aloud CHICAGO --- Imagine seeing a furry, four-legged animal that meows. Mentally, you know what it is, but the word “cat” is stuck on the tip of your tongue. This phenomenon, known as Broca’s aphasia or expressive aphasia, is a language disorder that affects a person’s ability to speak or ...

Next-gen Alzheimer’s drugs extend independent living by months

2025-02-13

In the past two years, the Food and Drug Administration has approved two novel Alzheimer’s therapies, based on data from clinical trials showing that both drugs slowed the progression of the disease. But while the approvals of lecanemab and donanemab, both antibody therapies that clear plaque-causing amyloid proteins from the brain, were greeted with enthusiasm by some Alzheimer’s researchers, the response of patients has been muted. According to physicians who care for people with Alzheimer’s, many patients found it difficult to understand what the clinical trials results — presented as “percent decrease in ...

Jumping workouts could help astronauts on the moon and Mars, study in mice suggests

2025-02-13

Jumping workouts could help astronauts prevent the type of cartilage damage they are likely to endure during lengthy missions to Mars and the Moon, a new Johns Hopkins University study suggests. The research adds to ongoing efforts by space agencies to protect astronauts against deconditioning/getting out of shape due to low gravity, a crucial aspect of their ability to perform spacewalks, handle equipment and repairs, and carry out other physically demanding tasks. The study, which shows knee cartilage in mice grew healthier following jumping exercises, appears ...

Guardian molecule keeps cells on track – new perspectives for the treatment of liver cancer

2025-02-13

A guardian molecule ensures that liver cells do not lose their identity. This has been discovered by researchers from the German Cancer Research Center (DKFZ), the Hector Institute für Translational Brain Research (HITBR), and from the European Molecular Biology Laboratory (EMBL). The discovery is of great interest for cancer medicine because a change of identity of cells has come into focus as a fundamental principle of carcinogenesis for several years. The Heidelberg researchers were able to show ...

Project Cure CRC ignites innovation in 2025 with $10.5 million in research, K-SPY debut & renewed RFP

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: